Author Correction: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial (Nature Medicine, (2022), 28, 10, (2155-2161), 10.1038/s41591-022-01962-5)

LCMC study investigators

Research output: Contribution to journalComment/debate

Abstract

Correction to: Nature Medicine. Published online 12 September 2022. In the version of this article initially published, the first sentence of the Fig. 4a caption (now reading “The expression of different NK cell surface receptors was determined by scRNA-seq”) was incorrectly preceded by the text “Association between gene expression in NK cells and the percentage of viable tumor cells,” which has now been removed from the HTML and PDF versions of the article.

Original languageEnglish
Pages (from-to)303
Number of pages1
JournalNature medicine
Volume30
Issue number1
DOIs
StatePublished - Jan 2024

Fingerprint

Dive into the research topics of 'Author Correction: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial (Nature Medicine, (2022), 28, 10, (2155-2161), 10.1038/s41591-022-01962-5)'. Together they form a unique fingerprint.

Cite this